Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of November 2, 2026, CLYM trades at $10.00 with a market cap of $588.72M and a P/E ratio of -12.21. CLYM moved -2.45% today. Year to date, CLYM is +173.33%; over the trailing twelve months it is +415.07%. Its 52-week range spans $1.05 to $18.33. Analyst consensus is strong buy with an average price target of $28.60. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for CLYM, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $10.00 |
| Market Cap | $588.72M |
| P/E Ratio | -12.21 |
| EPS | $-0.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.33 |
| 52-Week Low | $1.05 |
| Volume | 2.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.85M |
| Gross Margin | 0.00% |
12 analysts cover CLYM: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.60.